JP2020523137A - 患者の血液に抗凝固剤を添加するための方法及び装置 - Google Patents
患者の血液に抗凝固剤を添加するための方法及び装置 Download PDFInfo
- Publication number
- JP2020523137A JP2020523137A JP2019568750A JP2019568750A JP2020523137A JP 2020523137 A JP2020523137 A JP 2020523137A JP 2019568750 A JP2019568750 A JP 2019568750A JP 2019568750 A JP2019568750 A JP 2019568750A JP 2020523137 A JP2020523137 A JP 2020523137A
- Authority
- JP
- Japan
- Prior art keywords
- anticoagulant
- blood
- patient
- value
- tbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008280 blood Substances 0.000 title claims abstract description 71
- 210000004369 blood Anatomy 0.000 title claims abstract description 71
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 52
- 229940127219 anticoagulant drug Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000000747 cardiac effect Effects 0.000 claims abstract description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 30
- 229960002897 heparin Drugs 0.000 claims description 30
- 229920000669 heparin Polymers 0.000 claims description 30
- 238000000502 dialysis Methods 0.000 claims description 27
- 230000001419 dependent effect Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 description 13
- 206010016717 Fistula Diseases 0.000 description 5
- 230000003890 fistula Effects 0.000 description 5
- 230000010100 anticoagulation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000000701 coagulant Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3675—Deactivation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/26—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving
- A61M1/267—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes and internal elements which are moving used for pumping
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/029—Measuring or recording blood output from the heart, e.g. minute volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0478—Heparin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3389—Continuous level detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/04—Heartbeat characteristics, e.g. ECG, blood pressure modulation
Abstract
Description
Qhep=Vhep/B=Vhep/2分
Claims (14)
- 患者の血液にボーラス投与の形で抗凝固剤を添加する方法であって、
ボーラス投与時間Bが、前記患者の血液量を表すTBVの値と、前記患者の心拍出量を表すCOの値とに依存する、
ことを特徴とする方法。 - 前記ボーラス投与時間は、T=TBV/COの値以上である、
請求項1に記載の方法。 - 前記抗凝固剤は、該抗凝固剤の体積流量をQhep、投与すべき前記抗凝固剤の体積をVhepとした場合、Qhep=Vhep/Bの速度で投与される、
請求項1又は2に記載の方法。 - 前記抗凝固剤はヘパリンである、
請求項1ないし3のいずれか1項に記載の方法。 - 前記抗凝固剤の前記添加は、ポンプによって行われる、
請求項1ないし4のいずれか1項に記載の方法。 - 前記抗凝固剤の前記添加は、血液治療装置の、具体的には透析装置の体外回路内に行われる、
請求項1ないし5のいずれか1項に記載の方法。 - 前記抗凝固剤の前記添加は、前記患者の血液治療の前に、具体的には前記患者の透析治療の前に行われる、
請求項1ないし6のいずれか1項に記載の方法。 - 前記TBVの値及び/又は前記COの値は、前記抗凝固剤の添加前に求められ、又はメモリから読み出される、
請求項1ないし7のいずれか1項に記載の方法。 - 患者の血液にボーラス投与の形で抗凝固剤を添加するための装置であって、前記患者の血液量を表すTBVの値と、前記患者の心拍出量を表すCOの値とに依存してボーラス投与時間Bを決定する手段を備え、さらに、
特定のボーラス投与時間B内に前記抗凝固剤を投与する手段をさらに有する、
ことを特徴とする装置。 - 前記ボーラス投与時間Bを決定する手段は、B≧Tの関係が満たされるように設計されている、
請求項9に記載の装置。 - 前記装置は、TBV及び/又はCOを求める手段を有し、及び/又は、前記TBVの値及び/又は前記COの値を記憶した、前記装置がアクセスできる又は前記装置の構成要素であるメモリが設けられる、
請求項9又は10に記載の装置。 - 前記抗凝固剤を投与する手段は、好ましくは前記抗凝固剤を血液治療装置の体外血液回路内に送り込むように構成されたポンプとして設計され、及び/又は、前記抗凝固剤はヘパリンである、
請求項9ないし11のいずれか1項に記載の装置。 - 前記装置は、血液治療装置の、好ましくは透析装置の構成要素であり、又は血液治療装置に、好ましくは透析装置に接続される、
請求項9ないし12のいずれか1項に記載の装置。 - 血液治療装置、具体的には透析装置であって、請求項9ないし13のいずれか1項に記載の装置を少なくとも1つ有する、
ことを特徴とする血液治療装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102017113061.6A DE102017113061A1 (de) | 2017-06-14 | 2017-06-14 | Verfahren und Vorrichtung zur Zugabe eines Antikoagulans in das Blut eines Patienten |
DE102017113061.6 | 2017-06-14 | ||
PCT/EP2018/065891 WO2018229229A1 (de) | 2017-06-14 | 2018-06-14 | Verfahren und vorrichtung zur zugabe eines antikoagulans in das blut eines patienten |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020523137A true JP2020523137A (ja) | 2020-08-06 |
JP7222927B2 JP7222927B2 (ja) | 2023-02-15 |
Family
ID=62684786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019568750A Active JP7222927B2 (ja) | 2017-06-14 | 2018-06-14 | 患者の血液に抗凝固剤を添加するための方法及び装置 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11571503B2 (ja) |
EP (1) | EP3638341B1 (ja) |
JP (1) | JP7222927B2 (ja) |
CN (1) | CN110769870B (ja) |
DE (1) | DE102017113061A1 (ja) |
WO (1) | WO2018229229A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113769192A (zh) * | 2021-08-20 | 2021-12-10 | 健帆生物科技集团股份有限公司 | 血液净化设备的控制方法、血液净化设备及存储介质 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007160101A (ja) * | 2005-12-13 | 2007-06-28 | Up Management Gmbh & Co Med-Systems Kg | 希釈装置およびコンピュータプログラム |
JP2010533553A (ja) * | 2007-07-17 | 2010-10-28 | メドラッド インコーポレーテッド | 心肺機能の評価、及び流体搬送の手順のパラメータを決定する装置、システム及び方法 |
JP2012501210A (ja) * | 2008-08-27 | 2012-01-19 | デカ・プロダクツ・リミテッド・パートナーシップ | 血液透析システム、血液透析カセット、および透析装置の作動方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3985123A (en) * | 1975-07-17 | 1976-10-12 | Avco Everett Research Laboratory, Inc. | Method and means for monitoring cardiac output |
US4898675A (en) * | 1983-08-15 | 1990-02-06 | Lavender Ardis R | System and method for continuously fractionating blood in situ |
US5421812A (en) * | 1992-03-04 | 1995-06-06 | Cobe Laboratories, Inc. | Method and apparatus for controlling concentrations in tubing system |
WO1996025186A2 (en) * | 1995-02-07 | 1996-08-22 | Gensia, Inc. | Feedback controlled drug delivery system |
US5656027A (en) * | 1995-06-06 | 1997-08-12 | Cobe Laboratories, Inc. | Surgical fluid suction accumulator and volume measurement device |
US8337444B2 (en) * | 2001-05-22 | 2012-12-25 | Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California | Measurement of cardiac output and blood volume by non-invasive detection of indicator dilution for hemodialysis |
US8372025B2 (en) * | 2005-09-22 | 2013-02-12 | Baxter International Inc. | Automation and optimization of CRRT treatment using regional citrate anticoagulation |
US8133194B2 (en) * | 2006-02-22 | 2012-03-13 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US20140199193A1 (en) | 2007-02-27 | 2014-07-17 | Deka Products Limited Partnership | Blood treatment systems and methods |
US20090326510A1 (en) * | 2008-06-30 | 2009-12-31 | Haefner Paul A | Drug Delivery Methods and Systems |
JP5379082B2 (ja) * | 2010-06-29 | 2013-12-25 | 猛 柴田 | 血液浄化装置 |
SG10201800720YA (en) * | 2011-05-24 | 2018-03-28 | Deka Products Lp | Blood treatment systems and methods |
EP3015124B1 (en) * | 2014-10-31 | 2017-08-16 | B. Braun Avitum AG | System for flexible citrate anticoagulation during extracorporeal blood treatment using feed-forward control |
US10589016B2 (en) * | 2015-04-15 | 2020-03-17 | Gambro Lundia Ab | Treatment system with infusion apparatus pressure priming |
-
2017
- 2017-06-14 DE DE102017113061.6A patent/DE102017113061A1/de not_active Ceased
-
2018
- 2018-06-14 WO PCT/EP2018/065891 patent/WO2018229229A1/de unknown
- 2018-06-14 US US16/622,331 patent/US11571503B2/en active Active
- 2018-06-14 JP JP2019568750A patent/JP7222927B2/ja active Active
- 2018-06-14 CN CN201880040011.9A patent/CN110769870B/zh active Active
- 2018-06-14 EP EP18732722.6A patent/EP3638341B1/de active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007160101A (ja) * | 2005-12-13 | 2007-06-28 | Up Management Gmbh & Co Med-Systems Kg | 希釈装置およびコンピュータプログラム |
JP2010533553A (ja) * | 2007-07-17 | 2010-10-28 | メドラッド インコーポレーテッド | 心肺機能の評価、及び流体搬送の手順のパラメータを決定する装置、システム及び方法 |
JP2012501210A (ja) * | 2008-08-27 | 2012-01-19 | デカ・プロダクツ・リミテッド・パートナーシップ | 血液透析システム、血液透析カセット、および透析装置の作動方法 |
Also Published As
Publication number | Publication date |
---|---|
JP7222927B2 (ja) | 2023-02-15 |
EP3638341B1 (de) | 2021-03-31 |
CN110769870B (zh) | 2022-07-15 |
US20200197597A1 (en) | 2020-06-25 |
CN110769870A (zh) | 2020-02-07 |
DE102017113061A1 (de) | 2018-12-20 |
WO2018229229A1 (de) | 2018-12-20 |
EP3638341A1 (de) | 2020-04-22 |
US11571503B2 (en) | 2023-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6821441B2 (en) | Method for the purification of blood by means of hemodialysis and/or hemofiltration and apparatus for performing said method | |
US10172994B2 (en) | Hemodiafiltration method | |
US7351218B2 (en) | Device and process for extracorporeal treatment by citrate anticoagulant | |
CN110944692B (zh) | 用于操作血液治疗设备的方法、用于执行该方法的控制单元和治疗设备 | |
JP2011509131A (ja) | フィステル再循環および心肺再循環の全再循環に対するフィステル内の再循環および/または心肺再循環の比率を求める方法 | |
Brandl et al. | A target-orientated algorithm for regional citrate-calcium anticoagulation in extracorporeal therapies | |
JP7222927B2 (ja) | 患者の血液に抗凝固剤を添加するための方法及び装置 | |
Kutschka et al. | A new minimized perfusion circuit provides highly effective ultrasound controlled deairing | |
CN107073194B (zh) | 用于制备体外血液回路以用于血液治疗的方法和设备 | |
JP2021090755A (ja) | 体外血液循環デバイス | |
Ferrari et al. | Safety and effectiveness of veno-venous extracorporeal membrane oxygenation combined with continuous renal replacement therapy | |
JP2016007541A (ja) | 体外循環による血液浄化のための装置 | |
Grooteman et al. | Practical guide to performing high volume hemodiafiltration | |
Bellomo et al. | Continuous Renal Replacement Therapy: Modalities and Their Selection | |
Condello et al. | Long-term ECMO, efficiency and performance of EUROSETS adult AL ONE ECMO oxygenator | |
De Somer | Cardiopulmonary Bypass in Children and Infants | |
JP2021049060A (ja) | 血液浄化装置 | |
Katagiri et al. | Plasma Exchange | |
Scorgie et al. | Middle molecule adsorption from ultrafiltrate for use in intensive care medicine | |
Klarenbach et al. | Reduced requirement for erythropoietin with quotidian hemodialysis therapy | |
Aslam et al. | EKG is Unreliable in Detecting Potentially Lethal Hyperkalemia in Hemodialysis (HD) Patients | |
Thakar et al. | PREOPERATIVE RENAL FUNCTION MAY PREDICT POSTOPERATIVE INFECTION RISK | |
Diamond et al. | Procedures in critical care: Dialysis and apheresis | |
Gotch et al. | ACCESS RECIRCULATION (R) DOES NOT RESULT IN ERROR IN BLOOD Na MEASUREMENTS BY AN ON LINE CONDUCTIVITY CLEARANCE MONITOR (OLC) DURING DIALYSIS | |
Marangoni et al. | EFFECTS OF PICOTAMIDE TREATMENT ON PLASMA THROMBOXANE A2 (TxA2) AND FREE FATTY ACID (FFA) RISE DURING HEMODIALYSIS (HD) IN CHRONICALLY ANURIC UREMIC PATIENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210611 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220623 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220629 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220928 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7222927 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |